NICE rejects omalizumab for asthma in children – Healthcare Republic


News Fire

NICE rejects omalizumab for asthma in children
Healthcare Republic
Using omalizumab (Xolair) to treat children with persistent allergic asthma does not represent good value for NHS money, NICE has said.
Asthma drug decision 'nonsensical'The Press Association
Under-12s to be denied asthma jab… only if they live in EnglandDaily Mail
UK's NICE Rejects Novartis' Xolair Again In Kids Aged 6 To 11Wall Street Journal
Telegraph.co.uk –MadeForMums –Visit Bulgaria
all 26 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.